Life Science Investing C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Life Science Investing C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Life Science Investing C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
Life Science Investing C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Life Science Investing Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Life Science Investing C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society Annual Meeting
RZOLV Technologies Appoints Mary Ellen Thorburn to the Board of Directors; Announces the Retirement of Darryl Yea
Homerun Resources Inc. Announces Positive Results of Confirmation Testing by Minerali Industriali Engineering on the Santa Maria Eterna Silica Sand for the Manufacture of Antimony-Free Solar Glass
HyProMag USA Finalizes Long Term Lease for Dallas-Fort Worth Rare Earth Magnet Recycling and Manufacturing Hub
